{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T02:27:59Z","timestamp":1790216879659,"version":"4.1.0"},"reference-count":40,"publisher":"Georg Thieme Verlag KG","issue":"01","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropediatrics"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Background\u2003Due to the limited data from clinical trials and real-world settings in the realm of nusinersen, there is a need for further evidence. This study seeks to assess the impact of nusinersen, when combined with standard care, on bulbar function, respiratory function, and the necessity for respiratory support among pediatric patients with spinal muscular atrophy (SMA).<\/jats:p>\n                  <jats:p>Methods\u2003Prospective observational study, involving pediatric SMA patients (Types 1\u20133) undergoing nusinersen treatment at the Hospital Universitario Virgen del Roc\u00edo in Spain over at least 24 months. The cohort included 11 SMA type 1 patients, comprising 6 type 1b and 5 type 1c, 12 SMA type 2 patients, and 5 SMA type 3 patients.<\/jats:p>\n                  <jats:p>Results\u2003Twenty-eight pediatric patients were enrolled with the majority being male (n\u2009=\u200920). Patients with type 1 were diagnosed and received treatment significantly earlier than those with types 2 and 3 (p\u2009&lt;\u20090.001). Additionally, there was a longer period between diagnosis and the start of treatment in types 2 and 3 (p\u2009=\u20090.002). Follow-up revealed statistically improved functional and respiratory outcomes associated with earlier initiation of nusinersen treatment at 6, 12, and 24 months in all phenotypes. The ability to swallow and feed correctly remained unchanged throughout the study, with SMA type 1c patients maintaining oral feeding in contrast to patients with SMA type 1b. Notably, no deaths were recorded.<\/jats:p>\n                  <jats:p>Conclusions\u2003This study provides important insights into the real-world clinical progress of pediatric SMA patients and their response to nusinersen treatment, highlighting the significance of early intervention for better functional and respiratory outcomes.<\/jats:p>","DOI":"10.1055\/a-2379-7069","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T19:12:37Z","timestamp":1722885157000},"page":"002-011","source":"Crossref","is-referenced-by-count":9,"title":["Effect of Nusinersen on Respiratory and Bulbar Function in Children with Spinal Muscular Atrophy: Real-World Experience from a Single Center"],"prefix":"10.1055","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1600-0916","authenticated-orcid":false,"given":"Mirella","family":"Gaboli","sequence":"additional","affiliation":[{"name":"Paediatric Pulmonology Unit, Department of Paediatrics, Instituto de Biomedicina de Sevilla, IBiS\/Hospital Universitario Virgen del Roc\u00edo\/CSIC\/Universidad de Sevilla, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mercedes","family":"L\u00f3pez Lobato","sequence":"additional","affiliation":[{"name":"Paediatric Neurology Unit, Department of Paediatrics, Hospital Universitario Virgen del Roc\u00edo, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justo","family":"Valverde Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Paediatric Gastroenterology, Hepatology and Nutrition Unit, Department of Paediatrics, Hospital Universitario Virgen del Roc\u00edo, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Ferrand Ferri","sequence":"additional","affiliation":[{"name":"Paediatric Physical Medicine and Rehabilitation Department, Hospital Universitario Virgen del Roc\u00edo, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloisa","family":"Rubio P\u00e9rez","sequence":"additional","affiliation":[{"name":"Methodological and Statistical Management Unit, Fundaci\u00f3n para la Gesti\u00f3n de la Investigaci\u00f3n en Salud de Sevilla (FISEVI), Hospital Universitario Virgen del Roc\u00edo, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry A.","family":"Andrade Ruiz","sequence":"additional","affiliation":[{"name":"Methodological and Statistical Management Unit, Fundaci\u00f3n para la Gesti\u00f3n de la Investigaci\u00f3n en Salud de Sevilla (FISEVI), Hospital Universitario Virgen del Roc\u00edo, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Mar\u00eda","family":"L\u00f3pez-Puerta Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Spine Surgery, Department of Orthopaedic Surgery and Traumatology, Universitary Hospital Virgen del Roci\u0301o, Networking Biomedical Research Center in Bioengineering, Biomaterials and Nanomedicine (CIBER\u2013BBN), Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Madruga-Garrido","sequence":"additional","affiliation":[{"name":"Neurolog\u00eda Pedi\u00e1trica, Hospital Viamed Santa Angela de la Cruz and Neurolinkia, Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"issue":"04","key":"ref1","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","article-title":"Spinal muscular atrophy","volume":"33","author":"S J Kolb","year":"2015","journal-title":"Neurol Clin"},{"issue":"01","key":"ref2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.4103\/2231-0770.197512","article-title":"Very severe spinal muscular atrophy (Type 0)","volume":"7","author":"S Al Dakhoul","year":"2017","journal-title":"Avicenna J Med"},{"issue":"01","key":"ref3","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/s41572-022-00380-8","article-title":"Spinal muscular atrophy","volume":"8","author":"E Mercuri","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"01","key":"ref4","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jpeds.2012.05.067","article-title":"Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy","volume":"162","author":"M A Farrar","year":"2013","journal-title":"J Pediatr"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1750-1172-6-71","article-title":"Spinal muscular atrophy","volume":"6","author":"A D'Amico","year":"2011","journal-title":"Orphanet J Rare Dis"},{"issue":"03","key":"ref6","first-page":"194","article-title":"Nusinersen: a novel antisense oligonucleotide for the treatment of spinal muscular atrophy","volume":"24","author":"E E Neil","year":"2019","journal-title":"J Pediatr Pharmacol Ther"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"750742","DOI":"10.3389\/fphar.2021.750742","article-title":"Assessing the value of nusinersen for spinal muscular atrophy: a comparative analysis of reimbursement submission and appraisal in European countries","volume":"12","author":"A Blonda","year":"2022","journal-title":"Front Pharmacol"},{"issue":"02","key":"ref8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3233\/JND-180315","article-title":"Evaluation of children with SMA type 1 under treatment with nusinersen within the Expanded Access Program in Germany","volume":"5","author":"A Pechmann","year":"2018","journal-title":"J Neuromuscul Dis"},{"issue":"18","key":"ref9","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1702752","article-title":"Nusinersen versus sham control in infantile-onset spinal muscular atrophy","volume":"377","author":"R S Finkel","year":"2017","journal-title":"N Engl J Med"},{"issue":"01","key":"ref10","doi-asserted-by":"crossref","first-page":"e15310","DOI":"10.1111\/ped.15310","article-title":"The effects of nusinersen treatment on respiratory status of children with spinal muscular atrophy","volume":"64","author":"E Hepkaya","year":"2022","journal-title":"Pediatr Int"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/ppul.25142","article-title":"Assessment of respiratory muscles and motor function in children with SMA treated by nusinersen","volume":"56","author":"M G\u00f3mez-Garc\u00eda de la Banda","year":"2021","journal-title":"Pediatr Pulmonol"},{"issue":"03","key":"ref12","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/acn3.51276","article-title":"Type I SMA \u201cnew natural history\u201d: long-term data in nusinersen-treated patients","volume":"8","author":"M Pane","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13023-020-01414-8","article-title":"Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study","volume":"15","author":"F Audic","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"01","key":"ref14","doi-asserted-by":"crossref","first-page":"e15175","DOI":"10.1111\/ped.15175","article-title":"Respiratory outcome of spinal muscular atrophy type 1 patients treated with nusinersen","volume":"64","author":"A P Ergenekon","year":"2022","journal-title":"Pediatr Int"},{"issue":"06","key":"ref15","doi-asserted-by":"crossref","first-page":"fcac269","DOI":"10.1093\/braincomms\/fcac269","article-title":"Population-based assessment of nusinersen efficacy in children with spinal muscular atrophy: a 3-year follow-up study","volume":"4","author":"F EV Scheijmans","year":"2022","journal-title":"Brain Commun"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jpeds.2019.12.047","article-title":"Respiratory needs in patients with type 1 spinal muscular atrophy treated with nusinersen","volume":"219","author":"V A Sansone","year":"2020","journal-title":"J Pediatr"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpn.2020.11.004","article-title":"Children and young adults with spinal muscular atrophy treated with nusinersen","volume":"30","author":"D Osredkar","year":"2021","journal-title":"Eur J Paediatr Neurol"},{"issue":"02","key":"ref18","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/brain\/awac252","article-title":"Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy","volume":"146","author":"A Pechmann","year":"2023","journal-title":"Brain"},{"issue":"09","key":"ref19","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/jnnp-2017-317412","article-title":"Nusinersen for SMA: expanded access programme","volume":"89","author":"M A Farrar","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejpn.2022.04.006","article-title":"Mid- and long-term (at least 12 months) follow-up of patients with spinal muscular atrophy (SMA) treated with nusinersen, onasemnogene abeparvovec, risdiplam or combination therapies: a systematic review of real-world study data","volume":"39","author":"J Erdos","year":"2022","journal-title":"Eur J Paediatr Neurol"},{"issue":"06","key":"ref21","doi-asserted-by":"crossref","first-page":"796","DOI":"10.4103\/aian.AIAN_524_20","article-title":"Clinical experience of nusinersen in a broad spectrum of spinal muscular atrophy: a retrospective study","volume":"23","author":"A R Kim","year":"2020","journal-title":"Ann Indian Acad Neurol"},{"issue":"06","key":"ref22","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1111\/ene.15768","article-title":"Type I spinal muscular atrophy patients treated with nusinersen: 4-year follow-up of motor, respiratory and bulbar function","volume":"30","author":"M Pane","year":"2023","journal-title":"Eur J Neurol"},{"issue":"01","key":"ref23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/thoraxjnl-2020-216564","article-title":"Effect of nusinersen on respiratory function in paediatric spinal muscular atrophy types 1-3","volume":"77","author":"A Chacko","year":"2022","journal-title":"Thorax"},{"issue":"06","key":"ref24","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.nmd.2023.04.007","article-title":"Respiratory and sleep outcomes in children with SMA treated with nusinersen - real world experience","volume":"33","author":"K Gonski","year":"2023","journal-title":"Neuromuscul Disord"},{"issue":"05","key":"ref25","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.nmd.2022.02.001","article-title":"Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland","volume":"32","author":"A Tscherter","year":"2022","journal-title":"Neuromuscul Disord"},{"issue":"01","key":"ref26","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s13023-018-0926-z","article-title":"Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: methodological uncertainties","volume":"13","author":"C Pontes","year":"2018","journal-title":"Orphanet J Rare Dis"},{"issue":"03","key":"ref27","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.nmd.2017.11.004","article-title":"Diagnosis and management of spinal muscular atrophy: Part 2: pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics","volume":"28","author":"R S Finkel","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1651-2227.2006.tb02379.x","article-title":"WHO Motor Development Study: windows of achievement for six gross motor development milestones","volume":"450","author":"WHO Multicentre Growth Reference Study Group","year":"2006","journal-title":"Acta Paediatr Suppl"},{"issue":"06","key":"ref29","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1183\/20734735.012113","article-title":"The Global Lung Function Initiative: dispelling some myths of lung function test interpretation","volume":"9","author":"S Stanojevic","year":"2013","journal-title":"Breathe"},{"issue":"04","key":"ref30","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3233\/JND-200614","article-title":"Oral and Swallowing Abilities Tool (OrSAT) for Type 1 SMA patients: development of a new module","volume":"8","author":"B Berti","year":"2021","journal-title":"J Neuromuscul Dis"},{"issue":"03","key":"ref31","first-page":"216","article-title":"Delphi consensus on recommendations for the treatment of spinal muscular atrophy in Spain (RET-AME consensus)","volume":"37","author":"I Pitarch Castellano","year":"2022","journal-title":"Neurologia (Engl Ed)"},{"issue":"01","key":"ref32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13023-019-1287-y","article-title":"Management and current status of spinal muscular atrophy: a retrospective multicentre claims database analysis","volume":"15","author":"J Darb\u00e0","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"11","key":"ref33","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1111\/ene.15501","article-title":"Nusinersen in adult patients with 5q spinal muscular atrophy: a multicenter observational cohorts' study","volume":"29","author":"J F V\u00e1zquez-Costa","year":"2022","journal-title":"Eur J Neurol"},{"issue":"05","key":"ref34","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3233\/JND-230011","article-title":"Sex difference in spinal muscular atrophy patients - are males more vulnerable?","volume":"10","author":"J Sun","year":"2023","journal-title":"J Neuromuscul Dis"},{"issue":"03","key":"ref35","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3233\/JND-190465","article-title":"Feeding and swallowing problems in infants with spinal muscular atrophy type 1: an observational study","volume":"7","author":"A MB van der Heul","year":"2020","journal-title":"J Neuromuscul Dis"},{"issue":"05","key":"ref36","first-page":"813","article-title":"DEVOTE study exploring higher dose of nusinersen in spinal muscular atrophy: study design and part A results","volume":"10","author":"R S Finkel","year":"2023","journal-title":"J Neuromuscul Dis"},{"issue":"08","key":"ref37","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/jcph.884","article-title":"Population pharmacokinetics of nusinersen in the cerebral spinal fluid and plasma of pediatric patients with spinal muscular atrophy following intrathecal administrations","volume":"57","author":"K T Luu","year":"2017","journal-title":"J Clin Pharmacol"},{"issue":"07","key":"ref38","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1007\/s00431-023-04883-8","article-title":"New therapies for spinal muscular atrophy: where we stand and what is next","volume":"182","author":"L Antonaci","year":"2023","journal-title":"Eur J Pediatr"},{"issue":"06","key":"ref39","doi-asserted-by":"crossref","first-page":"e1002049","DOI":"10.1371\/journal.pmed.1002049","article-title":"Why most clinical research is not useful","volume":"13","author":"J P Ioannidis","year":"2016","journal-title":"PLoS Med"},{"issue":"01","key":"ref40","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s12874-022-01768-6","article-title":"Real-world data: a brief review of the methods, applications, challenges and opportunities","volume":"22","author":"F Liu","year":"2022","journal-title":"BMC Med Res Methodol"}],"container-title":["Neuropediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2379-7069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T18:48:22Z","timestamp":1737139702000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2379-7069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,5]]},"references-count":40,"journal-issue":{"issue":"01","published-online":{"date-parts":[[2025,1,17]]},"published-print":{"date-parts":[[2025,2]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2379-7069","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0174-304X","1439-1899"],"issn-type":[{"value":"0174-304X","type":"print"},{"value":"1439-1899","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,8,5]]},"published":{"date-parts":[[2024,8,5]]}}}